


Metallomics

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3 **The Copper Transporter 1 (CTR1) is Required to Maintain the Stability of Copper**
4
5 **Transporter 2 (CTR2)**
6
7
8
9


10 Cheng-Yu Tsai^a, Janika K. Liebig^a, Igor F. Tsigelny^b, Stephen B. Howell^{a,c}
11
12
13

14
15 ^aMoore's Cancer Center, ^bDepartment of Neurosciences and ^cDepartment of Medicine,
16
17 University of California, San Diego, 3855 Health Sciences Drive, Mail Code 0819, La Jolla, CA
18
19 92093-0819, USA,
20
21
22
23

24 To whom correspondence should be addressed: Stephen B. Howell, MD, Moore's UCSD Cancer
25
26 Center, 3855 Health Sciences Drive, Mail Code 0819, La Jolla, CA 92093-0819, USA; Tel. 1-
27
28 (858) 822-1110; Fax 1-(858) 822-1111; email: showell@ucsd.edu
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table of contents entry

We describe for the first time that the copper transporter 1 (CTR1) is important to maintain the stability of copper transporter 2 (CTR2)



Abstract

Mammalian cells have two influx Cu transporters that form trimers in membranes. CTR1 is the high affinity transporter that resides largely in the plasma membrane, and CTR2 is the low affinity transporter that is primarily associated with vesicular structures inside the cell. The major differences between CTR1 and CTR2 are that CTR1 contains a HIS/MET-rich domain N-terminal of the METS that participate in the first two stacked rings that form the pore, and a longer C-terminal tail that includes a Cu binding HIS-CYS-HIS (HCH) motif right at the end. It has been reported that CTR1 and CTR2 are physically associated with each other in the cell. We used the CRISPR-Cas9 technology to knock out either CTR1 or CTR2 in fully malignant HEK293T and OVCAR8 human ovarian cancer cells to investigate the interaction of CTR1 and CTR2. We report here that the level of CTR2 protein is markedly decreased in CTR1 knockout clones while the CTR2 transcript level remains unchanged. CTR2 was found to be highly ubiquitinated in the CTR1 knock out cells, and inhibition of the proteasome prevented the degradation of CTR2 when CTR1 was not present while inhibition of autophagy had no effect. Re-expression of CTR1 rescued CTR2 from degradation in the CTR1 knockout cells. We conclude that CTR1 is essential to maintain the stability of CTR2 and that in the absence of CTR1 CTR2 is degraded by the proteasome. This reinforces the concept that the functions of CTR1 and CTR2 are inter-dependent within the Cu homeostasis system.

Keywords: genome engineering; CRISPR/Cas9; copper transporter 1; copper transporter 2; protein stability.

Introduction

Cu is an essential element that cells must acquire from the environment. It is a cofactor for a large number of enzymes required for cell growth. Mammalian cells have two influx Cu transporters, CTR1 and CTR2. CTR1 is the high affinity transporter and resides largely in the plasma membrane. CTR2 has a lower affinity and, while some of it resides in the plasma membrane, the majority is associated with vesicular structures inside the cell¹. In yeast, CTR2 functions to mobilize Cu from the vacuole when Cu is scarce² but its role in mammalian cells is poorly defined. CTR1 and CTR2 share 41% amino acid homology and, as shown in Figure 1, their topology is very similar. Both have an extra-membranous N-terminal domain, 3 transmembrane domains and a C-terminal tail and when present in the plasma membrane the N-terminal is extracellular and the C-terminal intracellular³⁻⁵. CTR1 contains 190 amino acids whereas CTR2 is only 143 amino acids long. Cryo-electron microscopy of CTR1 demonstrated that it forms a trimer in the plasma membrane^{6,7}, and biochemical studies indicate that CTR2 does as well¹. Both proteins contain a set of four MET in homologous positions; in the case of CTR1 these are known to be essential for Cu transport. Building on the cryo-electron microscopic data we created all-atom models of both CTR1 and CTR2 which show that when assembled into a trimer they create four stacked rings of three MET each as shown in the lower panels of Figure 1⁸. The four rings are perfectly aligned to form a pore, and the distances between the rings are such that Cu chelated by the upper ring can toggle down through the other rings in a series of transchelation reactions⁹.

The major differences between CTR1 and CTR2 are that CTR1 contains a HIS/MET-rich domain N-terminal of the METS that participate in the first two stacked rings, and a longer C-terminal tail that includes a Cu binding HIS-CYS-HIS (HCH) motif right at the end. CTR1

1
2
3 transports Cu^{+1} but not Cu^{+2} in an ATP independent manner. The extra N-terminal region present
4
5 in CTR1 has been proposed to concentrate Cu^{+2} ions and facilitate their reduction to Cu^{+1} ,
6
7
8 whereas the HCH in the C-terminal tail appears to function as a switch to open and close the pore
9
10 ^{7, 10-12}. While the HCH motif is quite far away from the MET rings above them, biochemical
11
12 studies indicate that these CYS bind Cu^{+1} and do influence Cu transport ¹³. Inward transport
13
14 appears to be driven by an affinity gradient with the N-terminal domain having lower affinity Cu
15
16 binding sites than the C-terminal end and the chaperones to which Cu^{+1} is handed ¹⁴. In addition
17
18 to the affinity gradient, the electronic charge structure introduced by the additional N- and C-
19
20 terminal sequences favors movement of Cu^{+1} from outside to inside through the CTR1 pore ⁸.
21
22 The ability of CTR1 to transport Cu^{+1} but not Cu^{+2} may be due to the fact that Cu^{+2} binds much
23
24 more tightly to MET than Cu^{+1} which may prevent Cu^{+2} from releasing from the first MET ring
25
26 so that it can toggle to the next ⁹. Ag is the only other metal ion known to be transported by
27
28 CTR1 and it too shares the characteristic of forming only weak bonds with MET ¹⁵.
29
30
31
32
33

34 CTR2 was identified as a Cu transporter on the basis of its homology to yCtr2, and its ability
35
36 to rescue the Cu deficient phenotype of *ctr1Δctr3Δ* mutants ³. In yeast, Ctr2 is localized in
37
38 vacuoles with the C-terminal tail oriented toward the cytosol. It has been shown that yCtr2
39
40 releases Cu from intercellular stores and delivers Cu to various chaperones under conditions of
41
42 Cu starvation ^{3, 16, 17}. However, the Ctr2-1 mutant of yeast Ctr2, that partially mislocalizes to the
43
44 plasma membrane, mediates Cu transport across the plasma membrane in a manner similar to
45
46 that of yCtr1 ². hCTR2 is also primarily localized to late endosomes and lysosomes, although it
47
48 has been reported to be on the plasma membrane in some cells ^{1, 18}. Mammalian CTR2 increases
49
50 Cu influx in cells in which it localizes to the plasma membrane although its affinity for Cu is less
51
52 than that of CTR1 ^{1, 18}. Like CTR1, CTR2 is able to bind Ag^{+} ; but not zinc, iron or manganese ¹.
53
54
55
56
57
58
59
60

1
2
3 Changes in CTR2 expression do not affect Cu efflux suggesting that it functions primarily as a
4 regulator of influx perhaps via control of intracellular sequestration and Cu storage^{1, 19-21}. It has
5 also been shown that CTR2 acts as an inhibitor of SOD1 protein expression, suggesting that
6 CTR2 may be integral to the regulation of other Cu proteins involved in Cu homeostasis¹.
7
8
9
10
11

12 The fact that CTR2 lacks the HIS/MET-rich in the N-terminal region, and the HCH motif in
13 the C-terminal end, has raised the question of whether it can really transport Cu or whether its
14 ability to alter cellular Cu levels is due to an effect on CTR1⁵. The all atom model of CTR2
15 suggests that the portion containing the four stacked MET rings (Figure 1C) may permit the
16 movement of Cu⁺¹ in either direction whereas the additional N- and C-terminal sequences
17 present in CTR1 may provide directionality to the movement of Cu. Alternatively CTR2 may
18 modulate Cu uptake by controlling the expression or function of CTR1. CTR2 has now been
19 shown to heterotrimerize with CTR1⁵ and control the level of a cleaved form of CTR1 that has
20 lost the N-terminal 40-45 amino acids that includes much of the HIS/MET-rich region and the
21 first two MET rings²². It has been proposed that it is the cleaved form of CTR1 rather than
22 CTR2 that mobilizes Cu from vesicular stores and that the ability of CTR2 to influence cellular
23 Cu may be the result of its ability to regulate CTR1.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Prior studies of the interaction of CTR1 and CTR2 have relied on mouse embryo
42 fibroblasts in which both alleles of CTR1 had been knocked out. These cells express very low
43 levels of either protein, and with a very few exceptions^{13, 23}, it has been very difficult to develop
44 antibodies that allow precise quantification or characterization of this transporter²⁴. The
45 CRISPR/Cas9 technology has become a powerful tool for gene editing and genome engineering.
46 A guide RNA can direct the Cas9 endonuclease to specific sites in the DNA where it creates a
47 double strand break. Errors made during non-homologous end-joining repair produce insertions
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and/or deletions (indels) that can disrupt the targeted gene. To further investigate the interaction
4
5 of CTR1 and CTR2 in a more tractable model that expresses higher levels of CTR1 we used the
6
7 CRISPR-Cas9 technology to knock out either CTR1 or CTR2 in fully malignant HEK293 and
8
9 OVCAR8 human ovarian cancer cells. We report here that the protein level of CTR2 was
10
11 markedly decreased in CTR1 knock out clones partly as a result of increased ubiquitination and
12
13 proteosomal degradation and that re-expression of CTR1 can rescue CTR2 from degradation.
14
15
16
17 Thus, CTR1 is essential to maintain the protein stability of CTR2.
18
19

20 Results

21 Knockout of CTR1 and CTR2 in HEK293T cells

22
23 Guide RNAs were selected with the assistance of the CRISPR Design Tool from the Zhang
24
25 laboratory at the Massachusetts Institute of Technology (<http://crispr.mit.edu/>) to target the
26
27 second exon of SLC31A1, the gene coding for CTR1, or the third exon of SLC31A2, the gene
28
29 coding for CTR2. Oligonucleotides homologous to the targeted sequences were ligated into the
30
31 BbsI site in the pSpCas9(BB)-2A-GFP (pX458) or pSpCas9(BB)-2A-Puro (pX459) vectors.
32
33 These vectors were transiently transfected into HEK293T cells and single surviving cells were
34
35 sorted by FACS into 96 well plates and expanded into populations. The targeted region in each
36
37 gene was amplified by PCR and the product sequenced. Approximately 15 clones were identified
38
39 in which editing had occurred in SLC31A1 and 15 clones in which editing had occurred in
40
41 SLC31A2. The specific mutations on the two alleles of candidate clones were identified by
42
43 TOPO-TA cloning of the PCR products followed by sequencing of multiple clones. The
44
45 sequence changes for the two CTR1^{-/-} and two CTR2^{-/-} clones selected for further study are
46
47 presented in Table 1. Clone CTR1 KO-1 contained a 7 nucleotide deletion on one allele and a 1
48
49 nucleotide insertion on the other whereas clone CTR1 KO-2 contained a 1 nucleotide insertion
50
51
52
53
54
55
56
57
58
59
60

1
2
3 on both alleles. Clone CTR2 KO-1 contained an 11 nucleotide deletion on both alleles whereas
4
5 clone CTR2 KO-2 contained a 24 nucleotide deletion on one allele and a 1 nucleotide deletion on
6
7 the other. The specific amino acid changes produced are shown in Table 2. In all cases, the
8
9 genomic editing resulted in either a truncated, out of frame or unstable form of CTR1 and CTR2.
10
11

12 **Knockout of CTR1 reduces CTR2 levels in HEK293T cells.**

13
14 The representative Western blot presented in Figure 2A shows that that there was no
15
16 expression of CTR1 in either of two CTR1^{-/-} clones, and no expression of CTR2 in either of two
17
18 CTR2^{-/-} clones indicating that lesions produced in the targeted sequences in each gene were
19
20 effective in eliminating expression of CTR1 and CTR2 at the protein level. While knockout of
21
22 CTR2 had no effect on the level of expression of CTR1, knockout of CTR1 unexpectedly
23
24 decreased the level of CTR2 in both CTR1^{-/-} clones. In the CTR1 KO-1 clone the level of CTR2
25
26 was only 22.3 ± 1.8 % of that in the wild type HEK293T cells, and in the CTR1 KO-2 clone it
27
28 was only 9.8 ± 1.8 % (Figure 2B, n = 4, p<0.001). To exclude the possibility that the decrease in
29
30 total CTR2 protein levels was due to a decrease in CTR2 mRNA, the CTR2 mRNA was
31
32 quantified by qRT-PCR. No change was expected because the lesions in these alleles do not stop
33
34 transcription of the gene and, as shown in Figure 2C, indeed there was no significant change in
35
36 CTR2 mRNA level in the CTR1^{-/-} or CTR2^{-/-} clones. Thus, the reduction in CTR2 appears to be
37
38 the result of a post-translation process.
39
40
41
42
43
44

45
46 Three lines of evidence argue that the reduction in CTR2 was not due low intracellular Cu
47
48 levels or a major perturbation of the Cu homeostasis system. First, as shown in Figure 3A there
49
50 was no significant difference in basal Cu content among the cells. Second, treatment of the
51
52 CTR1^{-/-} cells with 10 or 30 μM Cu for 24 h did not restore the CTR2 protein levels (Figure 3B).
53
54 Third, knockout of CTR1 did not produce major changes in the level of ATOX1, SOD1, CCS,
55
56
57
58
59
60

1
2
3 ATP7A and ATP7B as determined by Western blot analysis of whole cell lysates (Figure 3C).
4
5 Thus, the markedly reduced the level of CTR2 in the CTR1^{-/-} cells did not appear to be the
6
7 consequence of altered Cu homeostasis. This conclusion is buttressed by quantification of
8
9 plasma membrane CTR1 as determined by cell surface biotinylation. There was no reduction in
10
11 plasma membrane CTR1 in the CTR2^{-/-} cells suggesting that trafficking from the trans-Golgi to
12
13 the plasma membrane was intact in the absence of CTR2, and exposure to Cu triggered the
14
15 normal loss of CTR1 from the plasma membrane indicating that the CTR1 endocytotic
16
17 mechanism was intact (Figure 3D).
18
19
20
21

22 **CTR2 is degraded by the ubiquitin-proteasome pathway in CTR1 KO cells.**

23
24 The observation that the decrease of CTR2 protein level in CTR1 knockout clones was not
25
26 the result of a decrease in CTR2 mRNA or intracellular Cu level suggested that CTR1 is required
27
28 to maintain the stability of CTR2 and prevent its degradation by the proteasome. To test this
29
30 hypothesis, we first examined CTR2 half-life in wild type HEK293T and CTR1 KO-2 cells using
31
32 cycloheximide (CHX) pulse-chase assay. The endogenous CTR2 level in CTR1 KO-2 cells was
33
34 only 10% of that in wild type HEK293T cells. To accurately quantitate CTR2 protein level for
35
36 the determination of its half-life, a vector expressing a FLAG-tagged CTR2 was transiently
37
38 transfected into HEK293T and CTR1 KO-2 cells. Forty-eight h later the cells were treated with
39
40 CHX to block new CTR2 synthesis, and the CTR2 levels were determined as a function of time
41
42 by Western blot analysis using an anti-CTR2 antibody. The data presented in Fig. 4A and B
43
44 demonstrate that, in the wild type HEK293T cells the CTR2 level fell to 68.6 ± 9.2 % of its
45
46 initial level during the 3 h exposure to CHX. In contrast, in the CTR1 KO-2 cells the CTR2
47
48 level fell to only 34 ± 4.5 % of its initial level (n=3, p<0.05). These experiments indicated that
49
50 the CTR2 half-life is significantly shortened in the absence of CTR1.
51
52
53
54
55
56
57
58
59
60

1
2
3 We next determined whether CTR1 protects CTR2 from proteasomal degradation by
4 measuring CTR2 levels after treating the CTR1 knockout clones with either the reversible
5 proteasomal inhibitor bortezomib (BTZ) or the irreversible proteasomal inhibitor carfilzomib
6 (CFZ). First, CTR1 KO-2 cells were treated with 100 nM BTZ or CFZ for 4, 8 or 24 h (Figure
7 5A). The CTR2 level increased by 2.9 ± 0.3 and 5.1 ± 0.2 -fold after 8 and 24 h exposures to
8 BTZ, respectively; the level increased by 2.5 ± 0.009 and 3.6 ± 0.8 -fold after equivalent
9 exposures to CFZ. The effects of BTZ and CFZ were statistically equivalent. Although a 24 h
10 exposure produced a larger increase in CTR2, ~40 % of cells were dead at this point so an 8 h
11 exposure to BTZ was chosen for subsequent studies. Figure 5B shows that the maximal increase
12 in CTR2 achieved with an 8 h exposure to BTZ was attained at 100 nM and thus this
13 concentration was selected for subsequent experiments. These results establish that, in the
14 absence of CTR1, CTR2 is degraded by the proteasome. An 8 h exposure of the wild type
15 HEK293T cells to 100 nM BTZ produced no change in CTR2 level whereas it increased CTR2
16 by factors of 1.6 ± 0.2 and 2.2 ± 0.4 in the CTR1 KO-1 and CTR1 KO-2 cells, respectively
17 (Figure 5C). This indicated that, in the presence of CTR1, inhibition of the proteasome had no
18 effect on CTR2 level but that, in its absence, CTR2 is susceptible to proteosomal degradation.
19 Thus, CTR1 protects and stabilizes CTR2 under normal conditions. To exclude the possibility
20 that when CTR1 was absent CTR2 was also being degraded by autophagy the wild type
21 HEK293T cells and the CTR1 KO-1 and CTR1 KO-2 clones were exposed to 20 μ M
22 chloroquine for 8 h. Unlike BTZ and CFZ, chloroquine failed to increase the CTR2 level in the
23 CTR1 knockout cells when p62 was used as a positive control of the effectiveness of chloroquine
24 (Figure 6).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Proteins are marked for proteosomal degradation by ubiquitination. To determine whether
4 loss of CTR1 enhanced the ubiquitination of CTR2, the wild type HEK293T and CTR1 KO-1
5 were transfected with myc-tagged ubiquitin and 16 h later they were treated with 100 nM BTZ
6 for 8 h. Whole cell lysates were collected and equal amounts of total proteins were
7 immunoprecipitated with anti-CTR2 and subjected to immunoblot analysis with anti-CTR2 and
8 anti-myc antibody. Because there was no CTR2 in CTR2 KO-1 cells, CTR2 KO-1 cells were
9 used as a negative control of the specificity of anti-CTR2 antibody (Figure 7A, lanes 1 and
10 2). When the anti-CTR2 antibody was used to pull down CTR2 from the wild type cells only a
11 small amount of myc-tagged ubiquitin-CTR2 conjugate was immunoprecipitated. (The ubiquitin-
12 CTR2 conjugate appears as a smear above the antibody heavy chain band in Figure 6A). We
13 quantified the ubiquitin smear and normalized it to the amount of CTR2 pulled down in each
14 precipitation and the results are shown in Figure 7B. In the absence of inhibition of the
15 proteasome by BTZ, immunoprecipitation of CTR2 brought down 5.5 ± 1.6 -fold more ubiquitin-
16 CTR2 from the CTR1 KO-1 than the wild type cells. Following treatment with BTZ,
17 immunoprecipitation of CTR2 brought down 10.4 ± 2.3 -fold more ubiquitinated CTR2 from the
18 CTR1 KO-1 than the wild type cells (n=3). This is consistent with the concept that when CTR1
19 protects CTR2 in the wild type cells such that only a minor fraction is ubiquitinated at steady-
20 state whereas a much larger fraction is ubiquitinated when CTR1 is missing. We sought to
21 determine whether NEDD4, NEDD4L or XIAP could be the potential ubiquitin E3 ligase
22 responsible for the degradation of CTR2. NEDD4 and NEDD4L are the human homologs of
23 RSP5, a yeast E3 ligase that degrades γ CTR1^{25, 26} and XIAP is a Cu binding protein with
24 ubiquitin E3 ligase activity that degrades COMMD1 and CCS^{27, 28}. The wild type HEK293,
25 CTR1 KO-1 and CTR1 KO-2 cells were transfected with a combination of NEDD4 and
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 NEDD4L siRNAs, or with an XIAP siRNA. The knockdown efficiencies of three siRNAs were
4 more than 90 % in each type of cell. However, none produced a significant increase in the CTR2
5 level in any of the 3 cell types (Figure 7C). Therefore, XIAP, NEDD4 or NEDD4L are probably
6 not the key ubiquitin E3 ligase involved in the degradation of CTR2 in this model system.
7
8
9
10
11

12 **Re-expression of CTR1 in CTR1 KO cells rescues CTR2 from degradation.**

13
14 To provide further evidence that CTR1 stabilizes CTR2, CTR1 was re-expressed in the
15 HEK293 CTR1 KO-1 and CTR1 KO-2 cells. A lentiviral vector containing a blastocidin
16 resistance marker was constructed to express an N-terminal myc-tagged form of wild type
17 hCTR1. CTR1 KO-1 and CTR2 KO-2 cells were infected and selected with blastocidin to
18 generate the CTR1 KO-1^{myc-CTR1} and CTR1 KO-2^{myc-CTR1} cells. Figure 8A documents the re-
19 expression of CTR1 by Western blot analysis using an anti-CTR1 antibody. The re-expression of
20 CTR1 increased CTR2 by 2.2 ± 0.06 and 10.6 ± 0.8 - fold in the CTR1 KO-1 and CTR1 KO-2
21 cells, respectively. These results further support the conclusion that CTR1 is required for the
22 stability of CTR2.
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **CTR1 is required to maintain the level of CTR2 in human ovarian cancer cells.**

37
38 CTR1 and CTR2 influence the cellular pharmacology of cisplatin and carboplatin²⁹.
39 Although HEK293T cells are malignant they have an uncertain origin^{30,31}. To establish the
40 biologic relevance for a disease routinely treated with these drugs CTR1 and CTR2 were
41 knocked out using the same CRISPR-Cas9 technology in the OVCAR8 ovarian cancer cell line.
42 The nucleotide and amino acid changes found in two CTR1 and two CTR2 knockout OVCAR8
43 clones are presented in Table 1 and Table 2. The immunoblot analysis presented in Figure 8B
44 shows that knockout of CTR1 reduced the level of CTR2 to 30.2 ± 3.1 % of control in the CTR1
45 KO-1 clone and to 32.9 ± 11.1 % of control in the CTR1 KO-2 clone. As for the HEK293T
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 cells, knockout of CTR2 failed to affect the level of CTR1 in either the CTR2 KO-1 or the CTR2
4
5 KO-2 clone. Thus, the ability of CTR1 to stabilize CTR2 is not unique to the HEK293T cell line.
6
7 CTR1 were also re-expressed in the CTR1 knockout OVCAR8 clones. The re-expression of
8
9 CTR1 again restored CTR2 level increasing it by 5.5 ± 0.8 and 6.4 ± 2.1 -fold in the CTR1 KO-1
10
11 and CTR1 KO-2 cells, respectively. These results support the conclusion that CTR1 is required
12
13 for the stability of CTR2.
14
15

16 17 **Discussion**

18
19 Cu is required for the growth of human tumors and, although systemic depletion of Cu by
20
21 administration of Cu chelators by themselves has limited activity, recent studies have disclosed
22
23 situations in which oncogenic transformation creates demand for Cu that exposes unique
24
25 vulnerabilities. In particular, melanomas harboring the BRAF^{V600E} mutation are critically
26
27 dependent on the function of CTR1 and are hypersensitive to the Cu chelator tetrathiomolybdate
28
29 due to the fact that MEK1/2 is a Cu-dependent enzyme^{32,33}. This example points up the need to
30
31 understand the how CTR1 and CTR2 function to maintain Cu homeostasis in human tumors.
32
33
34
35

36
37 In part because of the difficulty in making high quality antibodies to CTR1 and CTR2, their
38
39 interaction has been difficult to study. The CRISPR-Cas9 technology now provides a facile
40
41 approach to definitively examining how the elimination of one protein affects the fate of the
42
43 other. Although the transfection efficiency of the HEK293T cells is substantially higher than
44
45 that of the OVCAR8 cells, little difficulty was encountered in isolating CTR1 and CTR2
46
47 knockout clones from either of these two malignant cell types.
48
49

50
51 We report here the novel observation that CTR1 protects CTR2 against proteosomal
52
53 degradation as shown schematically in Figure 8. We successfully knocked out CTR1 in
54
55 HEK293T and OVCAR8 cells. CTR2 is decreased in the CTR1 KO cells in both cell lines.
56
57
58
59
60

1
2
3 While the addition of Cu or inhibition of autophagy did not rescue CTR2 protein level,
4
5 proteosomal inhibitors did. Re-introduced CTR1 back to the CTR1 KO cells restored expression
6
7 of CTR2 indicating that CTR1 protects CTR2 from proteosomal degradation. As shown in
8
9 Figure 1, CTR1 and CTR2 exhibit substantial homology and our all-atom modeling suggests that
10
11 CTR2, like CTR1, forms a homotrimer in the membrane. Using a FRET based approach with
12
13 YFP on the carboxyl-terminal end of CTR1 and YFP on the amino-terminal end of CTR1,
14
15 Ohrvik *et al.* reported that CTR1 can form a heteromeric complex with CTR2. Thus, there is
16
17 evidence for a physical interaction that is likely to underlie the ability of each protein to protect
18
19 the other. No information is currently available regarding what percent of either protein is
20
21 complexed to the other, or the stoichiometry of the most abundant complexes. While more CTR1
22
23 is found in the plasma membrane than CTR2 by immunocytochemical analysis, there is a
24
25 substantial amount of CTR1 on intracellular membranes in many cells that may reflect the
26
27 distribution of heteromeric complexes. However, the observation that knockout of CTR1 resulted
28
29 a large reduction in CTR2 suggests that a substantial fraction of CTR2 is bound to CTR1 in some
30
31 fashion. In contrast, even in the CTR2 knockout cells, the majority of CTR1 is found in a non-
32
33 cleaved form suggesting that a smaller fraction of the total CTR1 pool is bound to CTR2. Where
34
35 the heteromeric complexes form during synthesis and intracellular distribution, and exactly how
36
37 CTR1 limits the proteolysis CTR2 remain important questions for future investigation.
38
39
40
41
42
43
44

45
46 Ohrvik *et al* (5) reported that the level of CTR2 regulated the N-terminal cleavage of CTR1
47
48 in both mouse embryo fibroblasts and HEK293 cells. The anti-CTR1 antibody available to us
49
50 does not detect the cleaved form of CTR1 and thus we were unable to assess the impact of the
51
52 loss of CTR2 on CTR1 structure in our knockout cells.
53
54
55
56
57
58
59
60

1
2
3 The fact that knockout of CTR1 causes loss of CTR2 complicates assessment of the
4 importance of each of these transporters as regulators of intracellular Cu and the cellular
5 pharmacology of cisplatin and carboplatin. We have previously shown, in both murine embryo
6 fibroblasts and in human ovarian cancer cells, that down regulation of CTR2 results in
7 hypersensitivity to cisplatin that is accompanied by increased cellular accumulation of the drug
8 ^{21, 34}. Since knockdown of CTR2 did not alter the level of CTR1 this effect might be ascribed to
9 CTR2 except for the possibility that if most of CTR2 exists in a heteromeic complex with CTR1
10 it may be the function of CTR1 that is changing. Likewise, the extent to which altering the
11 expression of CTR1 in different types of cells alters sensitivity to cisplatin is quite variable, a
12 result perhaps of the loss of CTR2 when CTR1 expression is suppressed.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 No information is known about the ubiquitin E3 ligase that controls the degradation of
28 CTR2. The only ubiquitin ligase known to degrade a Cu transporter is yeast Rsp5 which
29 degrades yCTR1³⁵. We were led to consider NEDD4 (neural precursor cell-expressed
30 developmentally down-regulated 4) and NEDD4-L (neural precursor cell-expressed
31 developmentally down-regulated 4-like) since these are the human homologs of Rsp5. However,
32 knock down of NEDD4 and NEDD4-L failed to increase the level of CTR2 in the CTR1
33 knockout cells and there is no other evidence to suggest that either NEDD4 or NEDD4L regulate
34 the degradation of CTR1 or CTR2 in mammalian cells. CTR1 and CTR2 do not contain the PY
35 motifs (PPxY or LPSY) which are identified as binding partners for the NEDD4 proteins. The X-
36 linked inhibitor of apoptosis protein (XIAP) was identified as a Cu-binding protein and regulator
37 of Cu homeostasis in addition to its well-known role as a potent suppressor of apoptosis. XIAP
38 binds and ubiquitinates COMMD1 (copper metabolism domain containing 1) and CCS (copper
39 chaperone for superoxide dismutase) both of which play important roles in regulating Cu
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 homeostasis. The binding of XIAP to COMMD1 and CCS is via its BIR3 domain and there is no
4
5 evidence to suggest that BIR3 domains can bind to CTR2. Thus, identification of the E3 ligase
6
7 involved in CTR2 degradation will require further investigation.
8
9

10 11 12 **Experimental**

13 14 **Drugs and Reagents**

15
16 Detergent-compatible protein assay kit, *DC*TM Protein Assay was purchased from BioRad
17
18 Laboratories, Inc. (Hercules, CA). Bortezomib (BTZ, Velcade; Millenium Pharmaceuticals) was
19
20 obtained from the University of California San Diego Moores Cancer Center pharmacy.
21
22 Carfilzomib (CFZ), cycloheximidie (CHX) and chloroquine were obtained from Sigma Aldrich
23
24 (St. Louis, MO). Blasticidin and puromycin were both obtained from Thermo Fisher Scientific
25
26 (Waltham, MA). Anti-CTR1 primary antibody was a gracious gift from Dr. Marcus Kuo ³⁶.
27
28 Mouse monoclonal antibody to hCTR2 was obtained from the National Cancer Institute ³⁴. Anti-
29
30 myc primary antibody 9B11, anti-Na⁺/K⁺ ATPase antibody and XIAP siRNA were purchased
31
32 from Cell Signaling Technology, Inc. (Danvers, MA). Anti-SOD1 and anti-CCS antibody were
33
34 purchased from Santa Cruz Biotechnology (Dallas, Texas). Anti-ATOX1 and ATP7B antibodies
35
36 were purchased from Abcam (Cambridge, MA). Anti-ATP7A antibody was purchased from
37
38 NeuroMAb (The UC Davis/NIH). Anti-p62 primary antibody was from BD Biosciences (San
39
40 Jose, CA). TOPO TA cloning kit for sequencing was purchased from Life Technologies (Grand
41
42 Island, NY). siRNA negative control, NEDD4 and NEDD4L siRNAs and Lipofectamine
43
44 RNAiMAX were purchased from Life Technologies, Inc (Grand Island, NY)
45
46
47
48
49
50
51

52 53 **Cell types, Culture and Engineering**

54
55
56
57
58
59
60

1
2
3 HEK293T cells were obtained from the American Type Tissue Culture Collection. Parental
4 HEK293T and sublines were cultured in DMEM medium (HyClone; Logan, UT) supplemented
5 with 10 % fetal bovine serum (HyClone; Logan, UT), sodium pyruvate and glutamine. OVCAR8
6 ovarian cancer cells were obtained from Dr. Tom Hamilton, Fox Chase Cancer Center and
7 cultured in RPMI 1640 medium (HyClone; Logan, UT) supplemented with 10 % fetal bovine
8 serum at 37 °C, 5 % CO₂. The wild-type myc-tagged hCTR1 was constructed in the vector
9 pENTR/D-TOPO and then transferred to the pLenti6/V5-DEST by LR reaction as previously
10 described³⁷. The myc-CTR1^{WT} lentiviral particles were produced in HEK293T cells using the
11 ViraPower™ packaging kit (Invitrogen; Carlsbad, CA) and then transduced into the HEK293T
12 and OVCAR8 CTR1 KO-1 and CTR1 KO-2 cells under 8 µg/mL blasticidin selection.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Generation of CTR1 and CTR2 knock out cell lines using CRISPR Cas9 technology**

28
29 The single guide RNA (sgRNA) construction and delivery was done according to the Nature
30 Protocols³⁸. In brief, sgRNA design was based on CRISPR design (<http://crispr.mit.edu/>). The
31 sequence targeted in SLC31A1 was TATGGGGATGAGCTATATGG on the coding strand in
32 the second exon; the sequence targeted in SLC31A2 was TCGCAGAGACAGACGGGGAC on
33 the coding strand in the third exon. A set of self-complementary gRNA oligos corresponding to
34 these targets (SLC31A1: 5'-CACCGCATATAGCTCATCCCCATA-3' and 5'-
35 AAACCTATGGGGATGAGCTATATGC3') and SLC31A2 (5'-
36 GTCCCCGTCTGTCTCTGCGATGG-3' and 5'-AAACTCGCAGAGACAGACGGGGAC3-')
37 were purchased from Integrated DNA Technologies (Coralville, Iowa) and annealed and ligated
38 into pSpCas9(BB)-2A-GFP (pX458) or pSpCas9(BB)-2A-Puro (pX459) (Addgene, Cambridge,
39 MA) using T4 DNA ligase (New England Biolabs, Ipswich, MA) to generate GFP-Cas9 or
40 puromycin-Cas9 fusion plasmids co-expressed with sgRNA to allow screening or selection of
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 transfected cells. CRISPR plasmids were transiently transfected into HEK293T cells or
4
5 OVCAR8 cells using Lipofectamine 2000 (Life Technologies, Inc Grand Island, NY) according
6
7 to the manufacturer's protocol. Cells transfected with GFP-Cas9 plasmids were sorted 48 h after
8
9 transfection by fluorescence-activated cell sorting (FACS) based on GFP signal into individual
10
11 wells of 96-well plates and incubated for 2–3 weeks. The sorted clones were then expanded in
12
13 12-well plates, followed by extraction of genomic DNA for genomic PCR using standard
14
15 methods. Cells transfected with Puromycin-Cas9 plasmids were subject to 3 $\mu\text{g}/\text{mL}$ puromycin
16
17 selection 24 h after transfection for 48 h. Cells were then cultured in regular media until
18
19 confluent. Single clones were acquired as mentioned above. The editing at the target site of
20
21 candidate clones was confirmed by TOPO TA cloning of PCR products spanning the target site
22
23 according to manufacturer's protocol (Life Technologies, Grand Island, NY) followed by Sanger
24
25 sequencing of a minimum of 10 clones for knockout cell line.
26
27
28
29
30

31 32 **Quantitative real time PCR**

33
34 Total cellular RNA was isolated using the RNeasy mini kit (QIAGEN, Valencia, CA). First-
35
36 strand cDNA was synthesized using SuperScript II reverse transcriptase and random primers
37
38 (Life Technologies, Grand Island, NY). Quantitative real-time PCR was performed using the
39
40 Bio-Rad iCycler iQ detection system in the presence of SYBR Green I dye (Bio-Rad
41
42 Laboratories, Inc, Hercules, CA). GAPDH was used as reference gene and relative mRNA levels
43
44 were determined using the $2(-\Delta\Delta\text{Ct})$ method. A 1-unit difference of Ct value represents a two-
45
46 fold difference in the level of mRNA.). The forward and reverse primers for CTR2 were: 5'-
47
48 gtctgtctctcgcgatgtct-3' and 5'-gtctgtctctcgcgatgtct-3', respectively.
49
50
51
52

53 **Immunoprecipitation and Immunoblotting Procedure**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cells were harvested and washed twice with ice-cold PBS. The pelleted cells were lysed with RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1 % SDS, 0.5 % sodium deoxycholate, 1 % Triton X-100) plus protease and phosphatase inhibitors (Thermo Scientific, Pittsburg, PA). Protein concentrations were determined by detergent-compatible protein assay kit, *DC*TM Protein Assay (Bio-Rad, Hercules, CA). Equal amount of proteins were incubated with either anti-CTR2 or anti-myc antibody and protein A/G beads (Thermo Scientific, Pittsburg, PA) overnight at 4°C with end-over-end rotation. The beads were then washed 5 times with ice-cold RIPA buffer and proteins were eluted by incubating the beads with Laemmli's 2× sample buffer (125 mM Tris–HCl, pH 6.8, 2 mM EDTA, 6% SDS, 20% glycerol, 5% β-mercaptoethanol and 0.25% bromophenol blue) at 95 °C for 5 min and subjected to Western blot analysis using an antibody to the myc tag or to CTR2. Protein expression on the Western blots was quantified using an Odyssey Imaging System (Li-Cor Biosciences, Lincoln, NE) utilizing software version 3.0. Expression of CTR1 or CTR2 in the experimental cells was expressed as a percent of that in the control cells after normalization to the level of beta-actin ³⁹.

Measurement of CTR2 half-Life

Wild type HEK293T cells and CTR1 KO-2 clone were transfected with a vector expressing FLAG-tagged hCTR2 and 48 h later they were exposed to 5 µg/mL cycloheximide for 0, 30, 60, 90, 120 or 180 min. Cells were then washed three times with PBS, and lysates were harvested for immunoblotting as described above.

Modeling of hCTR2 Structure

The structure of the hCTR2 transporter was modeled using our model of CTR1 using the PDB databank fragments substitution module of the Homology program (Accelrys, San Diego) ⁸. The model underwent 10,000 iterations using Steepest Descent minimization.

RNAi knock down

HEK293T, CTR1 KO-1 and CTR1 KO-2 cells were seeded in six-well plates at a density of 0.25×10^6 cells/well. The following day siRNA was added to wells according to the manufacturer's instructions and incubated for 48 h before collection of cells for Western blot analysis.

Measurement Cu content

Whole cell Cu content was measured as previously reported⁴⁰. All data presented are the means of at least 3 independent experiments, each performed with 6 cultures per concentration tested.

Cell surface Biotinylation

The plasma membrane localization of CTR1 was measured by cell surface biotinylation as previously reported³⁷.

Statistical Analysis

All two-group comparisons utilized Student's *t*-test with the assumption of unequal variance. Data are presented as mean \pm SEM of a minimum of 3 independent experiments.

Acknowledgements

This work was supported by grants R01-CA152185 and T32CA121938 from the National Institutes of Health.

References

1. P. V. van den Berghe, D. E. Folmer, H. E. Malingre, E. van Beurden, A. E. Klomp, B. van de Sluis, M. Merckx, R. Berger and L. W. Klomp, *Biochem J*, 2007, **407**, 49-59.

- 1
2
3 2. E. Rees, J. Lee and D. Thiele, *J Biol Chem*, 2004, **279**, 54221-54229.
- 4
5 3. E. M. Rees and D. J. Thiele, *J Biol Chem*, 2007, **282**, 21629 - 21638.
- 6
7 4. S. Puig, J. Lee, M. Lau and D. J. Thiele, *Journal of Biological Chemistry*, 2002, **277**,
8 26021-26030.
- 9
10 5. H. Ohrvik, Y. Nose, L. K. Wood, B. E. Kim, S. C. Gleber, M. Ralle and D. J. Thiele,
11 *Proc Natl Acad Sci U S A*, 2013, DOI: 10.1073/pnas.1311749110.
- 12
13 6. C. J. De Feo, S. G. Aller and V. M. Unger, *Biometals*, 2007, **20**, 705-716.
- 14
15 7. C. J. De Feo, S. G. Aller, G. S. Siluvai, N. J. Blackburn and V. M. Unger, *Proceedings of*
16 *the National Acadademy of Sciences of the United States of America*, 2009, **106**, 4237-
17 4242.
- 18
19 8. I. F. Tsigelny, Y. Sharikov, J. P. Greenberg, M. A. Miller, V. L. Kouznetsova, C. A.
20 Larson and S. B. Howell, *Cell Biochem Biophys*, 2012, **63**, 223-234.
- 21
22 9. S. B. Howell, R. Safaei, C. A. Larson and M. J. Sailor, *Mol Pharmacol*, 2010, **77**, 887-
23 894.
- 24
25 10. Z. Xiao, F. Loughlin, G. N. George, G. J. Howlett and A. G. Wedd, *J Am Chem Soc*,
26 2004, **126**, 3081-3090.
- 27
28 11. Z. Xiao and A. G. Wedd, *Chemical Communications (Cambridge, England)*, 2002, 588-
29 589.
- 30
31 12. X. Wu, D. Sinani, H. Kim and J. Lee, *The Journal of Biological Chemistry*, 2009, **284**,
32 4112-4122.
- 33
34 13. E. B. Maryon, S. A. Molloy, K. Ivy, H. Yu and J. H. Kaplan, *J Biol Chem*, 2013, DOI:
35 10.1074/jbc.M112.442426.
- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14. L. Banci, I. Bertini, S. Ciofi-Baffoni, T. Kozyreva, K. Zovo and P. Palumaa, *Nature*, 2010, **465**, 645-648.
 15. J. Bertinato, L. Cheung, R. Hoque and L. J. Plouffe, *Molecular Biology*, 2010, **24**, 178-184.
 16. K. Kampfenkel, S. Kushnir, E. Babiychuk, D. Inze and M. Van Montagu, *J Biol Chem*, 1995, **270**, 28479-28486.
 17. M. E. Portnoy, P. J. Schmidt, R. S. Rogers and V. C. Culotta, *Mol Genet Genomics*, 2001, **265**, 873-882.
 18. J. Bertinato, E. Swist, L. J. Plouffe, S. P. Brooks and R. L'Abbe M, *Biochem J*, 2008, **409**, 731-740.
 19. J. Bertinato and M. R. L'Abbe, *J Biol Chem*, 2003, **278**, 35071-35078.
 20. S. Barhoom, M. Kupiec, X. Zhao, J. R. Xu and A. Sharon, *Eukaryot Cell*, 2008, **7**, 1098-1108.
 21. B. G. Blair, C. A. Larson, R. Safaei and S. B. Howell, *Clin Cancer Res*, 2009, **15**, 4312-4321.
 22. E. B. Maryon, S. A. Molloy and J. H. Kaplan, *J Biol Chem*, 2007.
 23. Y. Nose, L. K. Wood, B. E. Kim, J. R. Prohaska, R. S. Fry, J. W. Spears and D. J. Thiele, *J Biol Chem*, 2010, **285**, 32385-32392.
 24. J. F. Quail, C. Y. Tsai and S. B. Howell, *J Trace Elem Med Biol*, 2014, **28**, 151-159.
 25. B. Yang and S. Kumar, *Cell Death Differ*, 2010, **17**, 68-77.
 26. D. Rotin, O. Staub and R. Haguenaer-Tsapis, *J Membr Biol*, 2000, **176**, 1-17.
 27. E. Burstein, L. Ganesh, R. D. Dick, B. Van De Sluis, J. C. Wilkinson, L. W. Klomp, C. Wijmenga, G. J. Brewer, G. J. Nabel and C. S. Duckett, *Embo J*, 2004, **23**, 244-254.

- 1
2
3
4 28. G. F. Brady, S. Galban, X. Liu, V. Basrur, J. D. Gitlin, K. S. Elenitoba-Johnson, T. E.
5
6 Wilson and C. S. Duckett, *Mol Cell Biol*, 2010, **30**, 1923-1936.
7
8 29. P. Abada and S. B. Howell, *Met Based Drugs*, 2010, **2010**, 317581.
9
10 30. J. D. Cheng, M. Valianou, A. A. Canutescu, E. K. Jaffe, H. O. Lee, H. Wang, J. H. Lai,
11
12 W. W. Bachovchin and L. M. Weiner, *Mol Cancer Ther*, 2005, **4**, 351-360.
13
14 31. G. Jin, H. I. Kawsar, S. A. Hirsch, C. Zeng, X. Jia, Z. Feng, S. K. Ghosh, Q. Y. Zheng, A.
15
16 Zhou, T. M. McIntyre and A. Weinberg, *PLoS One*, 2010, **5**, e10993.
17
18 32. M. L. Turski, D. C. Brady, H. J. Kim, B. E. Kim, Y. Nose, C. M. Counter, D. R. Winge
19
20 and D. J. Thiele, *Mol Cell Biol*, 2012, **32**, 1284-1295.
21
22 33. D. C. Brady, M. S. Crowe, M. L. Turski, G. A. Hobbs, X. Yao, A. Chaikuad, S. Knapp,
23
24 K. Xiao, S. L. Campbell, D. J. Thiele and C. M. Counter, *Nature*, 2014, **509**, 492-496.
25
26 34. C. P. Huang, M. Fofana, J. Chan, C. J. Chang and S. B. Howell, *Metalloomics*, 2014, **26**,
27
28 654-661.
29
30 35. J. Liu, A. Sitaram and C. G. Burd, *Traffic*, 2007, **8**, 1375-1384.
31
32 36. M. T. Kuo, *Molecular Cancer Therapeutics*, 2012, **11**, 1221-1225.
33
34 37. C. Y. Tsai, C. A. Larson, R. Safaei and S. B. Howell, *Biochem Pharmacol*, 2014, **90**,
35
36 379-387.
37
38 38. F. A. Ran, P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott and F. Zhang, *Nat Protoc*,
39
40 2013, **8**, 2281-2308.
41
42 39. C. Y. Tsai, J. C. Finley, S. S. Ali, H. H. Patel and S. B. Howell, *Biochem Pharmacol*,
43
44 2012, **84**, 1007-1013.
45
46 40. C. A. Larson, B. G. Blair, R. Safaei and S. B. Howell, *Mol Pharmacol*, 2009, **75**, 324-
47
48 330.
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Homology between CTR1 and CTR2, Red: the extracellular N-terminal domains and the C-terminal domains of the CTR1 that not exists in CTR2; Green: the intracellular domain of CTR2 which is lacking in CTR1 (A), the ribbon presentation of all-atom models of CTR1 showing the positions of the stacked methionine triads of MET45, MET43, MET154, and MET150 and the side chains of histidines 188 and 190 are located close to each other in the C-terminal tail of hCTR1. (B) The ribbon presentation of all-atom models of CTR2 showing the positions of the stacked methionine triads of MET3, MET1, MET115, and MET111. (C). The methionines surrounding the entrance channel at N-terminal parts of CTRs are presented in CPK model with green for carbon and yellow for sulfur atoms.

Figure 2. Effect of knocking out CTR1 on CTR2 protein levels in HEK293T cells. (A) Basal CTR1 and CTR2 protein levels in CTR1 and CTR2 knockout cells. (B) Quantification of CTR1 and CTR2 protein levels in CTR1 and CTR2 knockout cells (N = 4, $p < 0.001$). (C) Relative levels of CTR2 mRNA in CTR1 and CTR2 knockout clones (n=6). Vertical, bars, \pm SEM; ***, $p < 0.001$

Figure 3. Cu homeostasis in CTR1 and CTR2 KO cells (A) Whole cell Cu content in CTR1 and CTR2 knockout cells comparing to WT cells. (B) Effect of Cu supplementation on CTR2 protein levels in CTR1 knockout cells. The immunoblot shown is representative of 3 independent

1
2
3 experiments. (C) ATOX1, SOD1, CCS, ATP7A and ATP7B protein levels in HEK293T WT,
4
5 CTR1 and CTR2 KO cells. The immunoblot shown is representative of 3 independent
6
7 experiments. (D) CTR1 plasma membrane levels and Cu-induced clearance of CTR1 from the
8
9 plasma membrane of CTR2 KO cells. Vertical, bars, \pm SEM

10
11
12
13
14
15 **Figure 4.** Effect of CTR1 knockout on the stability of CTR2. (A) Representative Western blot
16
17 showing CTR2 protein level in wild type HEK293T and CTR1 KO-2 cells after exposure to 5
18
19 $\mu\text{g/ml}$ cycloheximide for 0, 30, 60, 90, 120 or 180 min. (B) Plot of the percentage of remaining
20
21 CTR2 protein as a function of time after the start of cycloheximide treatment

22
23
24
25
26
27 **Figure 5.** Proteasomal inhibitors block degradation CTR2 in CTR1 knockout HEK293T cells.
28
29 (A) Effect of increasing duration of exposure to 100 nM BTZ or CFZ on CTR2 protein level in
30
31 CTR1 KO-2 cells. (B) Effect of an 8 h exposure to increasing BTZ concentrations on CTR2 level
32
33 in CTR1 KO-2 cells. (C) Effect of an 8 h exposure to 100 nM BTZ on CTR2 protein level in
34
35 CTR1 knockout clones. N = 3 for each histogram. Vertical, bars, \pm SEM; *, $p < 0.05$; **, $p < 0.01$;
36
37 *** $p < 0.001$.

38
39
40
41
42
43 **Figure 6.** The effect of chloroquine on CTR2 protein levels in wild type HEK293T, CTR1 KO-1
44
45 and CTR1 KO-2 cells. The immunoblot shown is representative of 3 independent experiments.

46
47
48
49
50
51 **Figure 7.** CTR2 is subject to ubiquitination in CTR1 knockdown cells. Wild type HEK293T
52
53 cells and the CTR2 KO-1 and CTR1 KO-1 clones were transfected with a vector expressing
54
55 myc-tagged ubiquitin and 16 h later treated with 100 nM BTZ for 8 h. (A) Whole cell lysates

1
2
3 were collected and equal amounts of total proteins were immunoprecipitated (IP) with anti-CTR2
4 and subjected to immunoblot (IB) analysis with anti-CTR2 (upper) and anti-myc antibody
5 (middle). Five percent of the total protein was used as input (bottom). CTR2 KO-1 cells were
6 used as a negative control for the anti-CTR2 antibody. The immunoblot shown is representative
7 of 3 independent experiments. (B) Quantitation of ubiquitinated CTR2 smear to amount of CTR2
8 in the immunoprecipitate (n=3). Vertical bars, \pm SEM; *, $p < 0.05$. (C) XIAP, NEDD4 and
9 NEDD4L were knocked down using siRNA in HEK293T, CTR1 KO-1 and CTR1 KO-2 cells
10 and CTR2 protein levels were measured. The immunoblot shown is representative of 3
11 independent experiments.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Figure 8.** Re-expression of CTR1 in CTR1 knockout cells rescues CTR2 in HEK293T and
28 OVCAR8 cells. (A) CTR1 and CTR2 protein levels were measured and quantified in HEK293T
29 wild type (WT), CTR1 KO-1, CTR1 KO-2, CTR1 KO-1^{mycCTR1} and CTR1 KO-2^{mycCTR1} cells. N
30 = 3. Vertical, bars, \pm SEM; ***, $p < 0.001$. (B) CTR1 and CTR2 protein levels were measured and
31 quantified in OVCAR8, CTR1 KO-1, CTR1 KO-2, CTR1 KO-1^{mycCTR1}, CTR1 KO-2^{mycCTR1},
32 CTR2 KO-1 and CTR2 KO-2 cells. N = 3. Vertical, bars, \pm SEM; *, $p < 0.05$; ***, $p < 0.001$
33
34
35
36
37
38
39
40
41
42

43 **Figure 9.** Proposed model of the regulation of CTR2 by CTR1. When CTR1 is present CTR2 is
44 protected from ubiquitination. When CTR1 is missing, CTR2 becomes ubiquitinated and is
45 subsequently degraded in the proteasome.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Genomic sequences of target sites in CTR1 and CTR2 knockout HEK293T and OVCAR8 clones.

CTR1		
	Allele 1	Allele 2
WT	ATGGATCATTCCCACCATATGG GGATGAGCTATAT	ATGGATCATTCCCACCATATGG GGATGAGCTATAT
HEK293T CTR1 KO-1	ATGGATCATTCCC ----- GG GGATGAGCTATAT(Δ 7)	ATGGATCATTCCCACCATATGG GGGATGAGCTATAT (+1)
HEK293T CTR1 KO-2	ATGGATCATTCCCACCATATGG GGGATGAGCTATAT (+1)	ATGGATCATTCCCACCATATGG GGGATGAGCTATAT (+1)
OVCAR8 CTR1 KO-1	ATGGATCATTCCCACCATATG- GGATGAGCTATAT (Δ 1)	ATGGATCATTCCCACCATATG- GGAT GAGCTATAT (Δ 1)
OVCAR8 CTR1 KO-2	ATGGATCATTCCCACCATATG - ----- ATAT(Δ 10)	ATGGATCATTCCCACCATATG - ----- ATAT(Δ 10)
CTR2		
	Allele 1	Allele 2
WT	CAGCAGACCATCGCAGAGACA GACGGGGACTCTGCAGGCTCAG ATTCATTCCC	CAGCAGACCATCGCAGAGACA GACGGGGACTCTGCAGGCTCAG ATTCATTCCC
HEK293T CTR2 KO-1	CAGCAGACCA - ----- GACGGGGACTCTGCAGGCTCAG ATTCATTCCC (Δ 11)	CAGCAGACCA - ----- GACGGGGACTCTGCAGGCTCAG ATTCATTCCCT (Δ 11)
HEK293T CTR2 KO-2	CAGCAGACCATCG- ----- ----- GCTCAG ATTCATTCCC(Δ 24)	CAGCAGACCATC - CAGAGACA GACGGGGACTCTGCAGGCTCAG ATTCATTCCC (Δ 1)
OVCAR8 CTR2 KO-1	CAGCAG - - - - - AGAGACA GACGGGGACTCTGCAGGCTCAG ATTCATTCCC (Δ 8)	- - - - - CAGAGACA GACGGGGACTCTGCAGGCTCAG ATTCATTCCC(Δ 13)
OVCAR8 CTR2 KO-2	CAGCAGACCATCG - AGAGACA GACGGGGACTCTGCAGGCTCAG ATTCATTCCC(Δ 1)	CAGCAGACCATCG - AGAGACA GACGGGGACTCTGCAGGCTCAG ATTCATTCCC(Δ 1)

Table 2. Amino acid sequences of target sites in CTR1 and CTR2 knockout HEK293T and OVCAR8 clones.

CTR1		
	Allele 1	Allele 2
WT	MDHSHHMGMSYMDSNSTMQPS HHHPPTSASHSHGGGDSSMMM MPMTFYFGF	MDHSHHMGMSYMDSNSTMQPS HHHPPTSASHSHGGGDSSMMM MPMTFYFGF
HEK293T CTR1 KO-1	MDHSRG*	MDHSHHMGDELYGLQQYHATFS PSPNHFSLTLPWRRRQQHDDDA YDLLLWL*
HEK293T CTR1 KO-2	MDHSHHMGDELYGLQQYHATF SPSPNHFSLTLPWRRRQQHDDD AYDLLLWL*	MDHSHHMGDELYGLQQYHATFS PSPNHFSLTLPWRRRQQHDDDA YDLLLWL*
OVCAR8 CTR1 KO-1	MDHSHHMG*	MDHSHHMG*
OVCAR8 CTR1 KO-2	MDHSHHMIWTPTVPCNLLTITQP LQPHTPMVEETAA*	MDHSHHMIWTPTVPCNLLTITQP LQPHTPMVEETAA*
CTR2		
	Allele 1	Allele 2
WT	QQTIAETDGDSAGSDSFPVGRTH HRWYLCHFGQSLIHVIQVVIGYFI	QQTIAETDGDSAGSDSFPVGRTH HRWYLCHFGQSLIHVIQVVIGYFI
HEK293T CTR2 KO-1	QQTRRGLCRLRFIPCWQ	QQTRRGLCRLRFIPCWQ
HEK293T CTR2 KO-2	QQTIGSDSFPVGRTHHRWYLCHF GQSLIHVIQVVIGYFI	QQTIRQTGTLQAQIHSLLAEPTT GGICVTLASL*
OVCAR8 CTR2 KO-1	QQRDRRGLCRLRFIPCWQNPPQV QAVGMGKGQKPHIHPRANSFKP	QRQTGTLQAQIHSLLAEPTTGTG SGYGKGAEASHSPKGEFV*
OVCAR8 CTR2 KO-2	QQTIERQTGTLQAQIHSLLAEPTT GTGSGYGKGAEASHSPKGEFV*	QQTIERQTGTLQAQIHSLLAEPTT GTGSGYGKGAEASHSPKGEFV*
*Premature stop codon that causes early termination		

A

CTR1: MDHSHHMGMSYMDSNSTMQPSHHHPTTSASHSHGGGDSSMMMMPMTFY

CTR2: - - - - - MAMHFI

CTR1: FGFKNVELLFSGLVINTAGEMAGAFVAVFLAMFYEGLKIARESLLRKSQVS

CTR2: FSDTAV - LLDFWSVHSPAGMALSVLVLLLAVLYEGIKVGKAKLL - - NQVL


CTR1: IRYNSMPVPGPNGTILMETHKTVGQQMLSFP - - - - - HLLQTVLH

CTR2: V - - - NLPTSISQQTIAETDGDSAGSD - - SFPVGRTHHRWYLCHFGQSLIH

CTR1: IIQVVISYFLMLIFMTYNGYL CIAVAAGAGTGYF - - - - LFSWKKAVVVDITEHCH

CTR2: VIQVVIGYFIMLAVMSYNTWIFLGVVVLSAVGYYLAYPLLSTA - - - - -

B



C




Figure 1




Figure 2







Figure 3

Metallomics Accepted Manuscript





Figure 4





Figure 5





Figure 6



C






Figure 7

Metallomics Accepted Manuscript






Figure 9